40 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
LLY Eli Lilly and Company $105.71 $113.53B N/A
Article Searches
Is the FDA Out to Get This $2.9 Billion Diabetes Drug Class? https://www.fool.com/investing/2019/09/05/is-the-fda-out-to-get-this-29-billion-diabetes-dru.aspx?source=iedfolrf0000001 Sep 05, 2019 - It’s rejected a pair of drugs in the last six months.
AstraZeneca's Tagrisso Gets Nod in China for First-Line NSCLC http://www.zacks.com/stock/news/503575/astrazenecas-tagrisso-gets-nod-in-china-for-first-line-nsclc?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-503575 Sep 05, 2019 - AstraZeneca's (AZN) Tagrisso gets a marketing approval in China for the first-line treatment of advanced or metastatic non-small cell lung cancer in patients with tumors having EGFR mutations.
Eli Lilly and Company (LLY) Presents At IASLC 2019 World Conference On Lung Cancer - Slideshow https://seekingalpha.com/article/4290610-eli-lilly-company-lly-presents-iaslc-2019-world-conference-lung-cancer-slideshow?source=feed_sector_healthcare Sep 09, 2019 - The following slide deck was published by Eli Lilly and Company in conjunction with this event.
Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice http://www.zacks.com/stock/news/510993/are-you-looking-for-a-high-growth-dividend-stock-eli-lilly-lly-could-be-a-great-choice?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_5-510993 Sep 10, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
Pharma Stock Roundup: Pipeline/Regulatory Updates From GSK, PFE & Others http://www.zacks.com/stock/news/516828/pharma-stock-roundup-pipeline-regulatory-updates-from-gsk-pfe-others?cid=CS-ZC-FT-analyst_blog|stock_roundup-516828 Sep 13, 2019 - Glaxo's (GSK) Nucala gets FDA nod for use in kids. Pfizer (PFE), Allergan (AGN) & Roche (RHHBY) give regular pipeline/regulatory updates.
AstraZeneca's Farxiga Gets Fast Track Tag for Heart Failure http://www.zacks.com/stock/news/521160/astrazenecas-farxiga-gets-fast-track-tag-for-heart-failure?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-521160 Sep 16, 2019 - The FDA assigns a Fast Track status to AstraZeneca's (AZN) Farxiga to reduce the risk of cardiovascular death or worsening of heart failure in adult patients with HFrEF and HFpEF.
Glaxo's Benlysta Gets Positive CHMP Opinion for Use in Kids http://www.zacks.com/stock/news/532006/glaxos-benlysta-gets-positive-chmp-opinion-for-use-in-kids?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-532006 Sep 23, 2019 - Glaxo's (GSK) SLE drug Benlysta gets a favorable CHMP opinion that recommends an approval for intravenous formulation in pediatric patients.
AstraZeneca Gets CHMP Nod for Forxiga/Onglyza Combo Tablet http://www.zacks.com/stock/news/533723/astrazeneca-gets-chmp-nod-for-forxiga-onglyza-combo-tablet?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-533723 Sep 24, 2019 - The CHMP recommends AstraZeneca's (AZN) marketing application for Qtrilmet, a combination of Forxiga and Onglyza plus metformin, for treating patients with type-II diabetes.
Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio http://www.zacks.com/stock/news/536794/why-eli-lilly-lly-is-a-top-dividend-stock-for-your-portfolio?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_5-536794 Sep 26, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
Novartis (NVS) Announces Data on Asthma Drugs & Kisqali http://www.zacks.com/stock/news/545899/novartis-nvs-announces-data-on-asthma-drugs-kisqali?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-545899 Oct 02, 2019 - Novartis (NVS) announces data from late-stage studies on asthma drugs and breast cancer drug, Kisqali.

Pages: 1234

Page 1>